{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-010729","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.597843+00:00","generated_at":"2026-05-26T23:58:06.126160+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Iovance appoints Dan Kirby as Chief Commercial Officer to lead Amtagvi launch expansion","bullets":["Dan Kirby appointed CCO effective February 10, 2025.","Kirby brings cell therapy commercial experience from Orca Bio, Omeros, Celgene/BMS, and Juno.","He will lead U.S. launch growth of Amtagvi and expansion of Proleukin sales.","Iovance also preparing to enter new international markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-010729","json":"https://secwatch.observer/filing/0001104659-25-010729.json","markdown":"https://secwatch.observer/filing/0001104659-25-010729.md","text":"https://secwatch.observer/filing/0001104659-25-010729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925010729/0001104659-25-010729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925010729/tm255949d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:58:06.126160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}